You are here

  • Home
  • Archive
  • Volume 31, Issue Suppl 3
  • 172 Efficacy and safety of maintenance olaparib by patient age in non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer in OPINION

Article info

Article menu

Download PDFPDF

Ovarian cancer
172 Efficacy and safety of maintenance olaparib by patient age in non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer in OPINION
Free

Authors

Citation

Skof E, Bjurberg M, Rubio Pérez M, et al
172 Efficacy and safety of maintenance olaparib by patient age in non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer in OPINION
International Journal of Gynecologic Cancer 2021;31:A202-A203.

Publication history

  • First published October 12, 2021.
Online issue publication 
January 10, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.